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Background: Liver cancer is a complex and burdensome disease, with Asia accounting for 75% of known cases.
Comprehensive cancer control requires the use of multiple strategies, but various stakeholders may have different
views as to which strategies should have the highest priority. This study identified priorities across multiple
strategies for comprehensive liver cancer control (CLCC) from the perspective of liver cancer clinical, policy, and
advocacy stakeholders in China, Japan, South Korea and Taiwan. Concordance of priorities was assessed across the
region and across respondent roles.
Methods: Priorities for CLCC were examined as part of a cross-sectional survey of liver cancer experts. Respondents
completed several conjoint-analysis choice tasks to prioritize 11 strategies. In each task, respondents judged which
of two competing CLCC plans, consisting of mutually exclusive and exhaustive subsets of the strategies, would
have the greatest impact. The dependent variable was the chosen plan, which was then regressed on the strategies
of different plans. The restricted least squares (RLS) method was utilized to compare aggregate and stratified
models, and t-tests and Wald tests were used to test for significance and concordance, respectively.
Results: Eighty respondents (69.6%) were eligible and completed the survey. Their primary interests were hepatitis
(26%), hepatocellular carcinoma (HCC) (58%), metastatic liver cancer (10%) and transplantation (6%). The most
preferred strategies were monitoring at-risk populations (p<0.001), clinician education (p<0.001), and national
guidelines (p<0.001). Most priorities were concordant across sites except for three strategies: transplantation
infrastructure (p=0.009) was valued lower in China, measuring social burden (p=0.037) was valued higher in Taiwan,
and national guidelines (p=0.025) was valued higher in China. Priorities did not differ across stakeholder groups
(p=0.438).
Conclusions: Priorities for CLCC in Asia include monitoring at-risk populations, clinician education, national guidelines,
multidisciplinary management, public awareness and centers of excellence. As most priorities are relatively concordant
across the region, multilateral approaches to addressing comprehensive liver cancer would be beneficial. However,
where priorities are discordant among sites, such as transplantation infrastructure, strategies should be tailored to
local needs.
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Hepatocellular carcinoma (HCC), the major histological
subtype of primary liver cancer, is the third leading cause
of cancer death worldwide [1-3]. In 2008, an estimated
749,000 people were diagnosed with liver cancer and
695,000 people died from it worldwide. The Asia-Pacific
region accounted for approximately 75% of known new
cases and deaths [3,4]. Hence, controlling liver cancer in
Asia is especially important for reducing its global
burden.
Most Asian governments have implemented policies
and laws to prevent Hepatitis B Virus (HBV) and Hepa-
titis C Virus (HCV) infection, seeking to control HCC
by targeting important risk factors. Universal hepatitis B
vaccination, the most effective method to prevent Hepa-
titis B [5], has been implemented in the majority of
Asian countries [6]. Top-down management of medical
settings, especially blood centers and blood banks, also
ensures the safety of blood products and reduces blood-
transmitted HBV and HCV infection [7]. Meanwhile,
screening programs for HBV infection, HCV infection
and HCC have also been implemented in various ways.
Routine HBsAg and anti-HCV tests are offered to volun-
tary blood donors in all Asian countries, and antenatal
exams are offered in most countries [6]. Periodic hepa-
titis testing among high risk populations is conducted
through national programs in Japan, South Korea and
Taiwan [6,8-10]. Public education campaigns in most
countries also play a major role in increasing the public’s
and physicians’ awareness of hepatitis and liver cancer
[6,11].
Although the above strategies help to reduce the
spread of hepatitis to a large extent, HCC incidence and
mortality rates are still increasing in Asia, mainly due to
the long natural history from hepatitis to HCC, and the
large existing population of HBV and HCV carriers [12].
Strategic national health plans specific to HCC control
are needed, but there is a paucity of literature devoted to
the optimal design of comprehensive liver cancer control
(CLCC).
The WHO provides some guidance for the creation of
comprehensive cancer control programs that can offer
some guidance for the creation of a CLCC [13]. Similar
targeted comprehensive cancer control plans have been
advocated and programs implemented for breast, cer-
vical, and colorectal cancer cancer [14-16]. To success-
fully implement CLCC, plans should reflect current
needs [17,18] and incorporate the views of a wide array
of stakeholders [13].
The objective of this study was to identify priorities
among multiple strategies for CLCC. Specifically we
engaged stakeholders involved in clinical, policy, and ad-
vocacy activities related to CLCC in China, Japan, South
Korea and Taiwan to document priorities and to test ifthey were concordant across the region and the stake-
holder groups. These results are of interest to health
care professionals and regulators in Asia, as well as their
counterparts in other countries as they can contribute to
national or regional efforts to implement CLCC. Our
contribution is also important to a wider audience as it
demonstrates a transparent and theoretically grounded
approach to involving stakeholders in priority setting
[19].Priority setting methods
If resources were unlimited, international and national
decision-makers could immediately adopt all available
CLCC strategies that could be expected to have an im-
pact based on existing evidence [20-26]. Implementation
is limited by a range of political, financial, human re-
source and time constraints, such that possible strategies
have to be prioritized even if it is envisioned that all
strategies will eventually be adopted [27,28].
Cost-effectiveness analysis (CEA) provides one way to
set priorities that focuses on allocating resources to
where they are (potentially) most beneficial [29]. CEA
has been criticized for inadequately incorporating the
view of stakeholders [30], ignoring many costs and bene-
fits that fall outside the health sector [31], and inaccur-
ately assessing the benefits of programs [32].
Furthermore, as a decision-making tool, it requires a
great deal of information about the costs and effects of
programs which may not be available and often lacks
transparency [33].
Other processes exist to study priorities that are less re-
strictive than CEA and, more importantly, allow for a
more transparent participation of stakeholders in decision
making. Traditionally deliberative process approaches
have been used that rely upon qualitative methods [34]
and Delphi approaches [35,36]. While such approaches
have an important role, they are grounded in normative
political theory, rather than some explicit theory of
prioritization [37]. Furthermore, the results of such ana-
lyses can be subject to the biases of the researchers or
facilitators [38], by dominant respondents [39] or misin-
terpretation [40]. While modern approaches to deliber-
ation, such as citizen juries [41] or Analytic Hierarchy
Process (AHP) [42] have overcome some of these con-
cerns, they are also more focused on decision making ra-
ther than the scientific study of priorities that may inform
decision makers.
While simple rating and ranking approaches can be
applied to priority setting exercises, they are subject to a
range of biases and complexities [43]. The self-
explicated methods, which combine ratings and rankings
in a multiplicative way in an attempt to minimize the
biases of rating and ranking alone, is one method that
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ence of a large number of factors [17,18,44].
Stated-preference methods, such as conjoint analysis
[45,46] and best-worst scaling (BWS) [47], offer a po-
tentially superior alternative to simple rating and
ranking methods as they ensure people have to make
tradeoffs [43]. Furthermore, as these methods can
utilize random utility theory (RUT), they are more
consistent with economic [48] and psychological [49]
theories of choice.
In conjoint analysis, the factors that are to be assessed
(which we might call objects to differentiate them from
attributes that may vary across defined levels) are pre-
sented in competing subsets (traditionally two) and
respondents are asked to make some judgment or choice
as to which of the sets are better [50]. The benefit of this
approach is that it reinforces the notion that multiple
objects are likely to incorporated in the eventual policy.
The downfall of this approach is that experimental
designs used to create such subsets are often based on
orthogonal or D-efficient designs that will lead to unba-
lanced numbers of objects in each subset [50]. Further-
more, such designs are generally “main-effects” which
implies that key interactions between the objects are not
estimated. Hence, one could not determine if objects
were considered complements or substitutes in the
minds of respondents.
In BWS case 1, which is known as the object case
[51], respondents are presented with subsets of the
objects and asked which subset is the best (with regards
to some criteria such as “which will have the greatest
effect?”) and which is worst on those same criteria. The
primary benefit of this approach is that it is a relatively
easy decision that is relatable to real life situations.
Researchers often use a balanced incomplete block de-
sign (BIBD) which ensures that there are the same
number of objects in each task (at the cost of orthog-
onality) [51,52]. The limitations of this method are that
it enforces the notion that one of the objects is the best
(rather than promoting that a portfolio of objects may
be optimal) and that, like conjoint analysis, interactions
are rarely explored.
Methods
Stakeholders are often consulted during policy processes
because they can provide critical insight overlooked by
more objective evaluation methods [53]. The WHO
recommended that policy makers incorporate stake-
holders’ input as part of a systematic and transparent
evaluation of priorities [19]. For the purpose of this
study we have chosen conjoint analysis as a means of in-
volving stakeholders in the prioritization of strategies
that could be incorporated into a CLCC plan. While this
approach has limitations, as detailed above, we thoughtit important to reinforce the notion that a CLCC plan
needed to incorporate multiple strategies.
In a previously published pilot study on this topic, the
conjoint analysis approach was shown to be both feasible
and functional even in a very low sample size (n=20)
[54]. Several limitations of the original study were identi-
fied and were corrected in this present application of the
technique. First, only a single stakeholder group (clini-
cians) was included; here we also have engaged both pol-
icy makers and advocates. Second, while a sample size of
20 was sufficient to measure aggregate priorities, we
have aimed to examine heterogeneity across sites in Asia
or across different stakeholder subgroups. Third, based
on the pilot results, and comparison with qualitative
data, several modifications to the survey instrument
were recommended in the previous publication [54] and
all have been incorporated here. Finally, the previous
publication used publication guidelines designed for
qualitative research, and not specifically targeted for
conjoint analysis. While other guidelines for conjoint
analysis have been proposed [55-58], this paper has
adhered to recently published guidelines for the applica-
tion of conjoint analysis in health care presented by the
International Society for Pharmacoeconomics and Out-
comes Research (ISPOR) [59].
Research question, perspective and rationale
The primary research question was to identify stake-
holder priorities across multiple strategies for CLCC in
Asia, to assess if these differed across clinical, policy,
and advocacy stakeholders and to explore the concord-
ance of priorities across China, Japan, South Korea and
Taiwan. Respondents were asked to use their own per-
spective in judging which strategies were better for their
country. As discussed above, conjoint analysis was
chosen as it is a valid method for assessing priorities and
preference heterogeneity, and as it reinforced the notion
that multiple strategies were needed if a CLCC were
to be successful. No priors were used for the purpose of
experimental design, and the hypotheses were centered
on identifying which factors were deemed valuable and
whether differences in priorities could be identified
across stakeholders or countries.
Selection of CLCC strategies
Data from previous qualitative interviews (n=20) with
international liver cancer clinicians were analyzed using
Interpretive Phenomenological Analysis to identify these
strategies [54]. A pilot was then conducted with clini-
cians from China, Japan, and Korea to assess the import-
ance of these strategies in comparison with the
qualitative data [54]. Based on this analysis, the wording
of the strategies surfaced as a potential limitation of
the pilot study. In order to avoid any ambiguity in
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ing the social burden of liver cancer” was relabeled
“Measuring incidence, prevalence and burden of liver
cancer” and the strategy “Improved risk-assessment and
referral by primary care” was relabeled “Early risk assess-
ment in primary care”. An explanation of the eleven
strategies presented in this conjoint analysis is presented
in Table 1.
Construction of choice tasks
These eleven strategies, which were considered as
being present or absent in a potential plan, were
assigned to one of two plans within each of the con-
joint analysis choice tasks by creating two mutually ex-
clusive and exhaustive subsets. This ensured all eleven
strategies appear at least once in each choice task, but
not twice. While there is some emerging evidence that
triplets have some benefits over paired choice tasks



























Measuring incidence, prevalence and


















National standards and guidelines The establishm
guidelines for
























surgical and oapplications in health [61]. As no country has adopted
CLCC we did not incorporate a status quo into the
choice tasks. An example of a choice task is illustrated
in Figure 1.
Experimental design
A main-effects orthogonal experimental design was used
to create the choice tasks [62]. This ensured zero collin-
earity among strategies and that importance of each
strategy could be estimated independently. This 2^11
design involved eleven columns of binary numbers, one
for each strategy, and twelve rows, which were translated
into the twelve conjoint-analysis choice tasks presented
in the survey. Here a strategy was placed on the left in a
task if the orthogonal array indicated a zero and on the
right if the orthogonal array indicated a one. Alternative
strategies were also considered, including designs based
on D-optimality and D-efficiency [59], but these
approaches would have led to identical designs underpatients and people that are at-risk of liver cancer have access to
medical care, including doctors’ ability to request screening and tests
n and asymptomatic disease through liver cancer prevention and
by governmental and/or private health insurance.
ients with liver cancer and other liver diseases that increase risk of liver
ical centers or research institutions with major liver disease
hat treat liver cancer and/or conduct the latest research in liver cancer.
r cancer centers to provide coordinated surveillance, treatment and
a national liver cancer program.
elated healthcare providers (primary care physicians, internists,
gists, hepatologists) about liver cancer, such as the importance of early
t, management of hepatic diseases to prevent progression to liver
health care costs or burden to the society, compared to screening,
n and management of liver cancer patients or at-risk people.
risk populations to detect liver diseases and liver cancer at an early
g the stratification of disease risk and hepatic disease surveillance in
risk of HCC.
mplex nature of liver cancer and multiple contributing factors, a highly
ciplinary team approach is necessary for managing liver cancer
non-surgically, as well as managing patients with hepatitis and other
ignificantly increase the risk of developing liver cancer.
ent and maintenance of nationwide, evidence-based standards and
the adoption of prevention, treatment and surveillance of liver cancer.
blic awareness of risk factors and prevention for liver disease as well as
the general population, including organized consumer liver disease
r advocacy.
structure, including capacity and qualified personnel, to conduct
linical and basic research in all stages of liver cancer, from prevention
isease treatment and care.
roved risk assessment and screening by primary healthcare providers
tioners, internists, gastroenterologists) and immediate referral of
iagnosed liver disease and/or liver cancer to medical experts specializing
ases and /or HCC.
splantation infrastructure and allocation of livers, including total liver
well as partial transplants from living donors; sufficient highly skilled
ther healthcare providers, latest transplant techniques and technology.
Figure 1 An example of a conjoint analysis choice task.
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tal design were assessed, confirming that the design was
orthogonal (both in terms of profiles and tasks), 100%
D-Optimal for main effects in a paired experiment, and
that level balance and zero overlap were achieved. Fi-
nally, with a design leading to only 12 choice tasks, the
respondent burden was deemed acceptable based on ex-
perience with the pilot study and given current stan-
dards [59,61].
Preferences elicitation and survey design
In each of the 12 choice tasks, stakeholders were asked
to choose the CLCC plan that they believed would have
a more significant impact in their country. As such, a
forced-choice preference elicitation procedure was used
that is consistent with the underlying theory [48,49].
Respondents were not asked to justify or explain theirpreferred strategy, and for simplicity strength of prefer-
ence or confidence in their answer was not explored.
Prior to preference elicitation, respondents were pro-
vided sufficient motivation about the strategies to facili-
tate an appropriate response. An example choice task
was also presented to confirm all respondents under-
stood how to complete the choice tasks correctly.
The questionnaire also collected background informa-
tion including respondents’ areas of involvement and
level of involvement in liver cancer control. The proper-
ties of the questionnaire were examined during the pilot
study and relevant modifications were noted above.Sampling strategy, ethical considerations and
data collection
Based on the experience from our pilot, a sample of 20
respondents per country was used or n=80 overall. Al-
though this is relatively small for a conjoint analysis
[61], we had to acknowledge that relevant experts in
liver cancer are not in endless supply. A strategy of pur-
posive quota sampling was used to ensure that a relative
balance of stakeholder types was recruited.
Clinical, policy, and advocacy stakeholders were
purposively selected equally from China, Japan, South
Korea and Taiwan. Potential respondents were ac-
tively involved in liver cancer prevention and control
activities as identified by authoritative literature, med-
ical and public health networks, peer referral and
leadership roles in government agencies, national cen-
ters or medical institutes/associations. Study inclusion
and exclusion criteria are shown in Table 2. Exclu-
sion criteria ensured all potential respondents were
familiar with national liver cancer control policy and
practice.
All respondents were informed about the study and its
potential risks and benefits. Respondents participated
voluntarily and were not reimbursed for participation.
The study was deemed exempt from the Institutional
Review Board (IRB) review at Johns Hopkins Bloomberg
School of Public Health.Data collection
Potential respondents were contacted for participation
via email or mail. Follow-up phone calls were made to
those who did not respond within two weeks. If there
was still no response after a maximum of four remin-
ders, they were considered as “no response”. Eligible
respondents were invited to complete the survey by
email or telephone. The survey was administered as an
interviewer-assisted face-to-face interview in English and
in the respondents’ native languages where necessary be-
tween October 2010 and April 2011.
Table 2 Inclusion and exclusion criteria
Role Inclusion criteria Exclusion criteria
Clinical Oncologists, surgeons, radiologists, other HCC and hepatobiliary
specialists, hepatologists, pathologists, and other specialists who
may be involved in HCC prevention, diagnosis, treatment and care,
or leaders of major medical institutions (including cancer and other
liver disease centers).
Not board certified, certified for less than one year, practicing
medicine for less than 3 years, living/practicing in country for less
than 3 years.
Policy Individuals in government, NGOs or other agencies involved in
public education, awareness and prevention related to liver disease
and liver cancer; national formularies and reimbursement decision-
making; the development of policy and/or guidelines for the
control of liver cancer; or those involved in policy related to liver
transplantation.
Less than 1 year’s experience in liver cancer and related fields; those
not directly involved in policies impacting liver cancer prevention
and control; or those with primary responsibilities as (and who
otherwise primarily identify themselves as liver cancer) clinicians,
advocates or in non-policy related roles.
Advocacy Recognized by liver cancer patients, physicians or policy leaders for
their national advocacy role; significant consumer/patient advocacy
of liver disease; leadership role in a nationally recognized advocacy
group; evidence of an active media and/or publication history that
is targeted to reach liver cancer patient or at-risk consumer
populations.
Those with primary responsibilities as clinicians or in non-advocacy
related roles; those whose scope of advocacy is limited to local
environs, i.e. with little/no national impact or recognition by peers,
clinical and policy leaders.
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Our data were structured so that an observation was
obtained for each of the 12 tasks across the 80 respon-
dents, leading to 960 observations (e.g. 12x80). The pri-
mary outcome (dependent variable) in the analysis was
the liver cancer control plan selected by the participant
for each task. Here each choice was coded as 1 if the re-
spondent chose the plan on the left or 0 if they choose
the plan on the right. The independent variables were a
set of eleven dichotomous variables indicating which
tasks were present. A strategy was coded as 1 if it was
presented in the plan on the left and −1 if it was pre-
sented in the plan on the right. The coding strategy is
required (as opposed to a traditional dichotomous vari-
able) because the absence of the strategy on the
left meant that it was automatically on the right. This
can be seen in a linear representation of the underlying
theory [48].
The difference in the value placed on the options (say
A and B) can be expressed as simply subtraction be-
tween the value placed on the attributes presented in A
and B respectively (denoted XA and XB), as presented in
eq. 1.
ΔV ¼ V XA  V XB  ½eq:1
Given that we have assumed linearity and have eleven
independent variables, we can think of the differences












As ΔV is unobserved, we need a mechanism to ap-
proximate it. As seen in eq. 3, our dichotomous variable
indicating which card was shown can approximate this
difference and be regressed against difference in thecards using ordinary least squares. The restricted regres-








Regressing the respondents’ choices on the strategies
produced a set of coefficients for the strategies which
will lead to the estimation of the βi, which will assess the
marginal valuation of each of the eleven strategies. These
estimated coefficients therefore showed the relative im-
portance of different strategies in a hypothetical liver
cancer control plan. The higher the value of the coeffi-
cients, the higher the strategy was prioritized. Coeffi-
cients with positive signs indicated the strategies were
valued, while negative signs indicated respondents were
opposed to those strategies.
To account for variation across our sample, say by
country, we can stratify the model by allowing the β to









 þ ε ½eq:4
Here we chose not to consider differences in the con-
stant term across the strata, as there was not theoretical
reason to suggest that the strata were particularly biased
to choose one side of the experiment over the other.
From eq. 4, differences across countries for each strat-
egy are tested by applying restricted least squares (RLS)
[63], using the βi1 = βi2 = βi3 = βi4 restriction, where the
RLS will produce a Wald statistic that tests the signifi-
cance of this restriction, and the overall test of differ-
ences across countries is conducted by testing all
restrictions on the eleven strategies at once. The same
model specification and Wald tests were used for the
model stratified by stakeholder type.
Table 3 Characteristics of respondents (n=80) stratified
by site




Clinicians 60.0 15.0 15.0 15.0 15.0 0.196
Hepatologist 18.8 2.5 5.0 7.5 3.8
Oncologist 21.3 10.0 2.5 1.3 7.5
Radiologist 3.8 1.3 1.3 1.3 0.0
Surgeon 12.5 0.0 8.3 4.2 0.0
Other 3.8 0.4 1.1 1.1 1.1
Policy makers 25.0 6.3 6.3 6.3 6.3 0.167
Governmental 18.8 5.0 6.3 5.0 2.5
Non-Governmental 6.3 1.3 0.0 1.3 3.8
Advocates 15.0 3.8 3.8 3.8 3.8 0.518
Disease advocacy 5.0 0.0 1.3 1.3 2.5
Media/Spokesperson 3.8 1.3 1.3 0.0 1.3




Hepatitis 26.3 5.0 11.3 3.8 6.3
HCC 57.5 17.5 13.7 16.3 10.0
Metastatic liver cancer 10.0 2.5 0.0 0.0 7.5




International 15.0 3.8 3.8 5.0 2.5
Local/municipality 6.3 5.0 0.0 1.3 0.0
National 56.3 13.7 11.3 17.5 13.7
Regional/provincial 22.5 2.5 10.0 1.3 8.8
*p<0.05, **p<0.01.
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estimates has a number of advantages over alternative
strategies. First, OLS does not require the assumption of
independence of irrelevant alternatives [48]. Second, the
difference between logit and OLS is generally found to
be small in conjoint analysis experiments [55,64]. Third,
given our main-effects orthogonal design and zero priors
on parameters, a linear model can be considered more
appropriate [64-66].
Robust standard errors were estimated to account for
the clustering of multiple observations from each re-
spondent. Analyses were conducted using Stata 11.2 for
Windows (StataCorp LP, College Station, TX). The t-test
and Wald test were used to test for significance and con-
cordance respectively. Pearson Chi-Square tests were
used to test for differences in stakeholder characteristics
across the region. All the parameter estimates are multi-
plied by 100 to aid interpretation.
Results
Eighty respondents were eligible and completed the sur-
vey (69.6% completion rate). As shown in Figure 2, 115
potential participants were invited to participate in the
study. Of these, 19 (16.5%) did not respond, 7 (6.1%)
refused to participate, 7 (6.1%) did not meet the inclu-
sion criteria and 2 (1.7%) did not complete the survey.
Table 3 shows stakeholders’ characteristics. Their pri-
mary roles were clinical (60%), policy (25%) and advo-
cacy (15%). Their main areas of involvement were
hepatitis (26.3%), hepatocellular carcinoma (57.5%),
metastatic liver cancer (10.0%), and transplantation
(6.3%). Respondents were involved in liver cancer con-
trol at international (15.0%), local/municipality (6.3%),
national (56.3%) and regional/provincial (22.5%) levels.
In the aggregate analysis, all eleven strategies were
positively valued and statistically significant (at p<0.01)
except for transplantation infrastructure. The most pre-
ferred strategy was monitoring at-risk populationsFigure 2 Study recruitment.(coefficient=13.75). The next preferred strategy was clin-
ician education (11.04), followed by national guidelines
(8.96), multidisciplinary management (8.33), public
awareness (8.13), centers of excellence (6.86), risk assess-
ment (5.42), access to treatments (5.21), measuring social
burden (5.21), and research infrastructure (3.96). The co-
efficient for transplantation infrastructure (0.42) was not
significantly different from zero (p=0.848), indicating it
was not expected to have a significant impact. The con-
stant term was not significantly different from 0.5 (50.2;
p=0.866), indicating no bias towards plans on the left or
the right.
In the subset analysis, we stratified the priorities by
sites and stakeholder groups, as shown in Table 4 and
Table 5. Priorities differed across countries (p<0.001). In
China, national guidelines (14.17; p<0.001) was valued
highest and transplantation infrastructure was valued
lowest (−8.33; p=0.025), as shown in Table 4. In Japan
and South Korea, monitoring at-risk populations (16.67
and 17.08 respectively; both p<0.001) was identified as
Table 4 Priorities stratified by site
Variable Aggregate China Japan South Korea Taiwan Chi-squared
p-valueCoef (SE) Coef (SE) Coef (SE) Coef (SE) Coef (SE)
Monitoring at-risk populations 13.75*** 9.17** 16.67*** 17.08*** 12.08*** 0.20
(1.5) (3.1) (2.7) (3.3) (2.5)
Risk Assessment 5.42*** 5.83* 0.83 7.08* 7.92** 0.18
(1.3) (2.4) (2.4) (2.9) (2.4)
Access to treatments 5.21*** 10.83*** 5.83* 1.25 2.92 0.11
(1.4) (3.0) (2.4) (2.7) (3.2)
National guidelines 8.96*** 14.17*** 10.00*** 7.92** 3.75 0.02*
(1.4) (2.8) (3.3) (2.7) (2.0)
Research infrastructure 3.96** 4.17 6.67* 3.75 1.25 0.63
(1.4) (2.5) (2.8) (2.5) (3)
Centers of excellence 6.86*** 5.83* 10.00*** 6.25* 5.42* 0.60
(1.5) (3.9) (2.5) (1.9) (3.1)
Multidisciplinary management 8.33*** 7.50** 11.67*** 6.25* 7.92** 0.44
(1.4) (2.4) (2.1) (3.4) (2.7)
Clinician education 11.04*** 7.50** 10.83*** 15.42*** 10.42*** 0.15
(1.3) (2.3) (3.2) (2.5) (2.6)
Public awareness 8.13*** 3.33 6.67* 11.25*** 11.25*** 0.11
(1.4) (2.7) (2.8) (2.7) (2.6)
Transplantation infrastructure 0.42 −8.33 5.83 −0.42 4.58 0.01**
(1.5) (3.6) (2.4) (2.7) (2.7)
Measuring Social Burden 5.21*** 2.50 2.50 2.92 12.92*** 0.04*
(1.4) (2.5) (2.7) (2.4) (3.1)
*p<0.05, **p<0.01, ***p<0.001, aggregate model R2=0.269, p<0.001, stratified model R2=.320.
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diverged: in Japan, risk assessment was valued lowest
(0.83; p=0.732) while transplantation infrastructure was
the lowest in South Korea (−0.42; p=0.877). In Taiwan,
measuring social burden (12.92; p<0.001) was valued
highest and research infrastructure was valued lowest
(1.25; p=0.677).
Table 5 compares the results among stakeholder
groups. Priorities differed across stakeholder groups
(p=0.001). Monitoring at-risk populations was most pre-
ferred by clinical and policy stakeholders (14.76 and
14.58 respectively; both p<0.001), while advocates valued
clinician education (13.89; p<0.001) highest. When it
came to least preferred strategy, all stakeholder groups
agreed on transplantation infrastructure (1.56, -2.92,
and 1.39 for clinical, policy and advocacy stakeholders
respectively; all p>0.05).
As there were slight differences among groups, we
tested for concordance across sites and stakeholder
groups. Most priorities were concordant across sites ex-
cept for three strategies: transplantation infrastructure
(p=0.009) was valued lower in China than Japan (−8.33
vs 5.83; p=0.002) and Taiwan (−8.33 vs 4.58; p=0.006);
measuring social burden (p=0.037) was valued signifi-
cantly higher in Taiwan than in China, Japan and Taiwan(12.92 vs 2.5, 2.5, and 2.92 respectively; all p<0.05); and
national guidelines (p=0.025) with higher valuations in
China than Taiwan (14.17 vs 3.75; p=0.003). In contrast,
priorities were concordant across stakeholder groups
with no differences for any of the strategies (all p>0.05).
Discussion
Strategies viewed as having the highest priority in Asia
were monitoring at-risk populations, clinician education,
national guidelines, multidisciplinary management,
public awareness, and centers of excellence. Priorities
were relatively concordant among the three groups of
stakeholders (clinical, policy, and advocacy) and across
the region. This said, three strategies, transplantation
infrastructure, measuring social burden, and national
guidelines received different priorities across the region.
The fact that most priorities are shared across the
four study sites provides justification for utilizing these
strategies in the sites we studied, and suggests the find-
ings could be generalized to other Asian countries with
similar situations.
The strategy of monitoring at-risk populations is
ranked as the top priority, consistent with some existing
actions. Three of the four sites already have monitoring
systems in place, suggesting either that the existing
Table 5 Priorities stratified by stakeholder role
Variable Aggregate Clinicians Policy Makers Advocates Chi-squared
p-valueCoef (SE) Coef (SE) Coef (SE) Coef (SE)
Monitoring at-risk populations 13.75*** 14.76*** 14.58*** 8.33* 0.28
(1.5) (2.0) (2.6) (3.6)
Risk Assessment 5.42*** 5.73** 2.92 8.33* 0.47
(1.3) (1.6) (2.7) (3.6)
Access to treatments 5.21*** 4.34* 6.25* 6.94 0.76
(1.4) (1.7) (3.6) (3.6)
National guidelines 8.96*** 9.55*** 7.08* 9.72** 0.79
(1.4) (1.7) (3.3) (3.6)
Research infrastructure 3.96** 5.03** −1.25 8.33* 0.08
(1.4) (1.6) (2.9) (3.3)
Centers of excellence 6.86*** 7.81*** 4.58 6.94 0.66
(1.5) (1.9) (3.0) (3.9)
Multidisciplinary management 8.33*** 9.20*** 7.92** 5.56 0.52
(1.4) (2.0) (2.3) (2.5)
Clinician education 11.04*** 11.28*** 8.75** 13.89*** 0.35
(1.3) (1.9) (2.4) (2.5)
Public awareness 8.13*** 9.20*** 3.75 11.11** 0.15
(1.4) (1.8) (2.5) (3.8)
Transplantation infrastructure 0.42 1.56 −2.92 1.39 0.47
(1.5) (2.1) (3.1) (3.6)
Measuring social burden 5.21*** 3.3 8.75** 6.94 0.25
(1.4) (1.6) (3.0) (4.8)
*p<0.05, **p<0.01, ***p<0.001, model R2=.287.
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hensive liver cancer control plan, or that the existing
system could be improved. South Korea, Japan and
Taiwan started national cancer screening programs in
the 1990s with liver cancer screening as an important
component [8,10,67]. Especially in Japan, where HCV
infection is a major etiological cause of liver cancer, a
HCV screening program has been implemented since
the late 1980s [10]. Japan’s National Project against
Hepatitis and HCC specifically focuses on screening
hepatitis carriers to prevent them from developing liver
cancer and also to detect early-stage liver cancer patients
[10]. Screening is an effective method to control liver
cancer and improve prognosis, and might be expected to
be one of the most important strategies for liver cancer
control given the large existing populations of HBV and
HCV carriers in most Asian countries [9].
The finding of heterogeneity in transplantation infra-
structure across sites is interesting. Respondents from
China valued this strategy extremely low, compared to
those from the other three sites. This phenomenon is con-
sistent with evidence of barriers to liver transplantation in
China. Although demand for liver transplantation has been
growing rapidly in China, ethical criteria and governing le-
gislation have not yet been fully established, which detersthe utilization of liver transplantation in liver cancer man-
agement [32,33]. Without legislation, the quality and safety
of liver transplantation are not supervised and guaranteed
for patients who undergo surgery, and the legal rights of
healthcare providers are not protected [68,69]. Faults in
the regulatory system also leave space for illegal organ
trades [68]. In addition, liver cancer transplantation is an
expensive surgical procedure that is not covered by health
care insurance in China, so affordability is another barrier
to full utilization [69]. Thus, it is reasonable that stake-
holders from China did not consider it a high priority des-
pite the fact that it is considered an effective treatment for
some liver cancer patients.
Our study demonstrated that conjoint analysis, a
stated preference method, can be utilized to prioritize
strategies for a comprehensive disease control plan. It
combines qualitative research methods with quantitative
methods, and provides a comprehensive way to explore
stakeholders’ judgments in the policy decision-making
process. Compared to CEA, the most prevalent
prioritization tool in health economics, conjoint analysis
has several advantages [31]. First, it can take into consid-
eration all possible outcomes (including risks and costs)
of health policies rather than just using a single meas-
urement to rank them [31]. Conjoint analysis can
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views are important when considering policy interven-
tions, hence the results are a useful step towards devel-
oping consensus. Indeed, our study found good
consensus among stakeholders from clinical, policy, and
patient advocacy roles, who together should have a good
understanding of decision making throughout their
health systems. Second, the theoretical basis of conjoint
analysis is less controversial than CEA, making it easier
to justify the method to stakeholders such as physicians
and policy makers [31].
This study demonstrated the usefulness of the
conjoint-analysis method in studying stakeholders' prior-
ities for CLCC strategies, although there are a number
of limitations that need to be considered. First, given
that the data come from subjective responses, there
might be some variations in preference due to respon-
dents’ specific positions, geography, or experience that
do not truly reflect societal preferences and cannot be
assessed with such a small sample. We tested concord-
ance across the three selected stakeholder groups, and
the results showed there was no statistically significant
heterogeneity. However, to ensure representativeness
and validity, additional important stakeholders should be
included in future studies, such as patients and health
policy researchers, and larger samples should be consid-
ered in countries such as China where there may be
large differences in disease burden and resources within
the country. In addition, if the sample size permitted, it
would be useful to incorporate a latent class analysis in
order to identify sources of heterogeneity that may not
be captured by the characteristics that we chose to
investigate.
A second limitation is that our study was conducted in
countries where English is not the native language. Al-
though the questionnaire was provided in both English
and respondents’ first languages, there might be some
misunderstandings due to translation.
The third limitation is that the generalizability of the
study is limited by the study sites that were selected.
Among our four sites, Japan, South Korea and Taiwan are
high-income countries, while China is different in terms of
health care resources, health financing and people’s socio-
economic status. As most Asian countries are low or mid-
dle income countries, the results may not be applicable to
all Asian countries. Further studies could be conducted in
low or middle income parts of Asia to examine whether
strategies are prioritized differently in such areas.
A fourth limitation of using conjoint analysis to assess
priorities is that respondents may have simply preferred
plans with more strategies than others. While all strat-
egies were positively correlated with the number of strat-
egies, this was uniform across the strategies, so bias in
the prioritization would be difficult. This said, we did re-estimate the aggregate model by holding constant the
number of attributes (which also required dropping the
intercept to avoid the dummy variable trap). We did
identify that there was a significant effect associated with
the number of strategies presented in the model
(p<0.001). In correcting for this bias, we found that only
five strategies were significantly different to zero and
positive (monitoring at-risk populations: 9.2, p<0.001;
clinician education: 6.5, p<0.001; national guidelines:
4.4, p=0.003; multidisciplinary management: 3.8,
p=0.008; and public awareness: 3.6, p=0.011) and one
was statistically significant and negative (transplantation
infrastructure: -4.1, p=0.011). In comparing these results
to those reported above, the exact prioritization across
the strategies was estimated. Future research is needed
on separating the number of objects in a conjoint from
the marginal effects estimated for each parameter.
Finally, the study sample size remains low and may
lack generalizability to other Asian countries. The ro-
bustness of the results obtained in the aggregate model
and the stratified models confirm the findings of the
pilot study that small sample sizes can be used [54]. This
said, the lack of statistical difference between the groups
can be attributed to the low sample size. While simula-
tion techniques may provide some benefit in overcoming
low sample sizes, such methods would also have to cor-
rect for the underlying differences in scale that may be
present across the strata.
Conclusions
This study has used a systematic and transparent
method to produce a prioritization of effective strategies
for liver cancer control in Asia. The finding of concord-
ance across four sites, despite differences in liver cancer
etiology and resources across sites, suggests that the pri-
orities are applicable to other parts of the region. The
results of this study constitute a ready-to-use, prioritized
plan for liver cancer control based on the views of key
stakeholders. The next step is for decision makers to im-
plement the priority strategies as comprehensive na-
tional plans and to instigate cross-national or regional
collaborations that can use the similarities in priorities
to improve liver cancer control across the region.
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